MedSci Healthcare (2415) H1 2024 earnings summary

Executive summary

• H1 revenue was RMB110.7m, down 26.9% YoY, as extended healthcare anti-corruption compliance reviews delayed project execution; gross profit fell 23.1% to RMB67.9m.

• Profit attributable to owners was RMB0.248m versus RMB11.920m; 2023 included a RMB12.785m fair-value gain on convertible redeemable preferred shares, with none in H1 2024.

Financial highlights

• Revenue was RMB110.7m, down 26.9% YoY; cost of sales was RMB42.7m, down 32.3%; gross profit was RMB67.9m, down 23.1%.

• Other income and gains rose to RMB18.9m from RMB13.2m, mainly on higher bank interest income; selling and distribution costs fell 23.9% to RMB37.9m.

• Administrative expenses increased 12.7% to RMB35.8m, mainly due to equity incentive expenses; R&D expenses fell 37.2% to RMB12.0m, with AI use and fewer developers cited.

• Loss before tax was RMB0.24m versus profit before tax of RMB12.9m; reported profit attributable to owners was RMB0.248m versus RMB11.920m.

Outlook and guidance

• Project execution speeds are expected to normalise gradually as compliance reviews conclude and new standards take effect.

• Priorities include expanding physician coverage, applying AI to improve efficiency, deepening disease-area expertise, increasing customer synergies and exploring international markets and strategic partnerships.

• Marketing plans emphasize compliant academic promotion, rare-disease expansion, pre-launch and one-stop commercialization solutions; RWS plans include digital targeting and AI-supported data management.